Martin Špaček
A5075093528- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Advanced Breast Cancer Therapies
- Tryptophan and brain disorders
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- Vitamin D Research Studies
- Immune Cell Function and Interaction
- Stress Responses and Cortisol
- Cytomegalovirus and herpesvirus research
- Multiple Myeloma Research and Treatments
- Cancer-related Molecular Pathways
- Epilepsy research and treatment
- Neuroendocrine regulation and behavior
- Education, Psychology, and Social Research
- Glycosylation and Glycoproteins Research
- Acute Myeloid Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- COVID-19 Clinical Research Studies
- Bipolar Disorder and Treatment
- Acute Lymphoblastic Leukemia research
- Heat shock proteins research
Charles University
2014-2025
General University Hospital in Prague
2014-2024
Klinik Bavaria
2018-2024
National and Kapodistrian University of Athens
2023
Centre for Research and Technology Hellas
2023
University Hospital Hradec Králové
2019
University Hospital Plzen
2019
LGBT Foundation
2019
Massachusetts General Hospital
2019
John Wiley & Sons (United States)
2019
The European Myeloma Network (EMN) organized two flow cytometry workshops. first aimed to identify specific indications for in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice participating laboratories. second resolve outstanding issues develop approach analysis plasma cells. primary clinical applications identified were: differential diagnosis neoplastic cell disorders from reactive plasmacytosis; identifying...
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study characterize course COVID-19 in and identify potential predictors outcome. Of 190 confirmed diagnosed between 28/03/2020 22/05/2020, 151 (79%) presented (need oxygen and/or intensive care admission). Severe was associated advanced...
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor outcome. Given increasing number new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce time necessary to assess their efficacy. this European Research Initiative on (ERIC) project we have identified and validated flow-cytometric approach reliably quantitate cells 0.0010% (10−5). The assay comprises core panel six markers (i.e. CD19,...
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility there is no consensus the role of new markers. aim this project was to identify reproducible markers recommended diagnosis CLL. ERIC/ESCCA members classified 14 35 potential as “required” or “recommended” diagnosis, being defined >75% >50% agreement, respectively. An approach validate using normal peripheral blood developed. Responses were received from...
Abstract Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due age, disease, and treatment-related immunosuppression. We aimed assess risk factors of outcome elucidate the impact CLL-directed treatments on course COVID-19. conducted a retrospective, international study, collectively including 941 patients CLL confirmed Data from beginning pandemic until March 16, 2021, were collected 91 centers. The case fatality rate (CFR),...
Abstract In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) related disorders (small lymphoma high‐count monoclonal B lymphocytosis) infected by SARS‐CoV‐2, including development post‐COVID condition. Data from 1540 CLL SARS‐CoV‐2 January 2020 to May 2022 were included in analysis assigned four phases based on cases disposition variants emergence. Post‐COVID condition was defined...
Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, impact CLL-related factors and CLL-directed treatment is still unclear represents focus this work. We conducted retrospective international multicenter study assess incidence OMs detect potential in 19,705 patients CLL, small lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 2016. Data collection took...
Progressing myelodysplastic syndrome (MDS) into acute myeloid leukemia (AML) is an indication for hypomethylating therapy (HMA, 5-Azacytidine (AZA)) and a BCL2 inhibitor (Venetoclax, VEN) intensive chemotherapy ineligible patients. Mouse models that engraft primary AML samples may further advance VEN + AZA resistance research. We generated set of transplantable murine PDX from MDS/AML patients who developed to compared the differences in hematopoiesis with bone marrow at genetic level. were...
Spacek M, Hubacek P, Markova J, Zajac Vernerova Z, Kamaradova K, Stuchly Kozak T. Plasma EBV-DNA monitoring in Epstein–Barr virus-positive Hodgkin lymphoma patients. APMIS 2010. virus (EBV) is associated with approximately one-third of (HL) cases. often present the plasma and whole blood EBV-associated HL However, significance debated. In a cohort 165 adult patients, viral load was prospectively monitored both blood. Diagnostic tissue samples all patients were histologically reviewed; 72%...
Summary Idelalisib (idela), a phosphatidylinositol 3‐kinase inhibitor, and ibrutinib, Bruton tyrosine kinase were the first oral targeted agents approved for relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R‐idela) versus ibrutinib have been conducted. Therefore, we performed real‐world retrospective analysis patients with R/R CLL treated R‐idela ( n = 171) or 244). The median age was 70 69 years, two previous lines....
Heat-shock proteins (Hsps) are thought to play a role in the development of cancer and modulate tumor response cytotoxic therapy. In this study, Hsp27, Hsp60, Hsp90α, HspBP1 gene expression was investigated human leukemia cell lines as well cells derived from patients with onset disease. Hsp70 membrane Hsp70, genes were also tested samples patients. Relative Hsps examined patients, using real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR). surface studied flow...
A simple, sensitive, fairly specific, and accurate procedure is described for the simultaneous quantitative determination of kynurenine p-phenetidine in human urine. It based on alkaline decomposition conjugated to yield o-aminoacetophenone p-phenetidine, respectively.
Summary There are limited data on retreatment with monoclonal antibodies ( mA b) in patients chronic lymphocytic leukaemia CLL ). In a pivotal study, ofatumumab (human anti‐ CD 20 monotherapy demonstrated 47% objective response rate ORR ) fludarabine refractory patients. From this subset of 29 who had at least stable disease and then progressed were retreated eight weekly infusions (induction treatment period), followed by monthly for up to 2 years (maintenance period). The after 8 weeks...
Abstract Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort real‐world patients performed matched adjusted indirect comparison treated ibrutinib. One hundred fifty‐seven creatinine clearance (CrCl) <70 mL/min and/or CIRS score >6 were BR. The median age was 72 years; 69% had ≥2 comorbidities CrCl 59.8 mL/min. 17.6%...
Abstract After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments 2) patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials real-world databases. Hazard ratios (HR) 95% confidence intervals (CIs) were estimated using a multivariate Cox proportional hazards model, adjusted for differences baseline...
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) shown to prolong progression free survival (PFS, median PFS-31.5 months) overall (OS) compared alone. More recently, given either ibrutinib or venetoclax improved PFS but not OS when O-Clb. this retrospective multinational, multicenter co-operative study, we evaluated the efficacy safety treatment O ± Clb CLL, a...
Abstract Background Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due the advanced age, presence of comorbidities, disease treatment-related immune deficiency. The aim this study was assess risk bleeding in patients CLL affected by severe COVID-19. Methods This is a retrospective multicenter conducted ERIC, European Research Initiative on CLL, from 79 centers across 22 countries. Data collection...
Checkpoint kinase 2 gene (CHEK2) codes for an important mediator of DNA damage response pathway. Mutations in the CHEK2 increase risk several cancer types, however, their role Hodgkin lymphoma (HL) has not been studied so far. The most frequent alterations (including c.470T>C; p.I157T) cluster into forkhead-associated (FHA) domain-coding region gene. We performed mutation analysis segment coding FHA domain using denaturing high-performance liquid chromatography 298 HL patients and analyzed...
Endothelial progenitor cells (EPCs) and circulating endothelial (CECs) have been described as markers of damage dysfunction in several diseases, including deep venous thrombosis. Their role patients with known thrombophilia has not yet evaluated. Both EPCs CECs represent extremely rare cell populations. Therefore, it is essential to use standardized methods for their identification quantification.In this study, we used multicolor flow cytometry analyze the number or without a history...
Summary Therapeutic options used to be very limited for treatment‐naïve elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphoma (CLL/SLL) before the introduction of chemo‐immunotherapy. Because dose‐reduced fludarabine‐based regimens yielded promising results, Czech CLL Study Group initiated a prospective observational study assess safety and efficacy low‐dose fludarabine cyclophosphamide combined rituximab (FCR) in patients. Between March 2009 July 2012, we enrolled 107...